share_log

Oppenheimer Initiates Coverage On Clarus Therapeutics Hldgs with Outperform Rating, Announces Price Target of $12

Oppenheimer Initiates Coverage On Clarus Therapeutics Hldgs with Outperform Rating, Announces Price Target of $12

奧本海默以優於大盤的評級啟動對Clarus治療公司Hldgs的覆蓋,宣佈目標價為12美元
Benzinga Real-time News ·  2021/09/20 08:19

Oppenheimer analyst Leland Gershell initiates coverage on Clarus Therapeutics Hldgs (NASDAQ:CRXT) with a Outperform rating and announces Price Target of $12.

奧本海默分析師Leland Gershell以優於大盤的評級啟動了Clarus Treateutics Hldgs(納斯達克市場代碼:CRXT)的報道,並宣佈目標價為12美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論